Cordlife Group (P8A) AI Stock Analysis

• Market Cap: S$38.30M
• Dividend Yield: N/A
• Average Volume (3M): 14.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: 2.83%
• EPS Growth: -0.71%
• Country: SG
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 267,525,360
• 10 Day Avg. Volume: 3,230
• 30 Day Avg. Volume: 14,193
• PEG Ratio: <0.01
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 1.38
• P/FCF Ratio: -2.46
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: S$0.16 ▲(21.54% Upside)

The score is held down mainly by weak profitability and cash flow (negative margins and negative operating cash flow), despite strong revenue growth and a low-leverage balance sheet. Technicals show short-term price strength but with overbought signals and a weaker longer-term trend. Valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Revenue Growth

Sustained ~17% TTM revenue growth demonstrates expanding market adoption of cord banking services across Asia. Over a 2–6 month horizon this growth supports higher lifetime customer value from annual storage fees, helps absorb fixed costs, and underpins scaling of processing capacity.

Low Leverage / Balance Sheet Strength

Extremely low leverage gives the company financial flexibility to invest in capacity, marketing, or regulatory compliance without urgent refinancing. Over months this reduces solvency risk, preserves optionality for partnerships or acquisitions, and cushions cash flow variability.

Recurring Revenue Model

The business combines upfront collection fees with recurring annual storage revenues, creating a predictable, high-retention revenue stream. Coupled with a reported ~56% gross margin, this model supports durable unit economics and revenue visibility over multiple years.

Negative Factors

Poor Profitability

Deep negative EBIT and net margins indicate core operating losses despite revenue growth. Persisting at current levels, these margins will erode equity, limit reinvestment capacity, and require substantial cost reductions or higher-margin service mix to achieve sustainable profitability over the medium term.

Weak Cash Generation

Negative operating cash flow and declining free cash flow growth show the business is consuming cash despite top-line gains. Over months this constrains capital allocation, may force external financing, and limits the firm's ability to fund expansion, quality controls, or strategic partnerships.

Negative Return on Equity

A negative ROE signals the company currently destroys shareholder value, reflecting weak profitability relative to equity. Over a 2–6 month horizon this undermines capital-raising ability, investor confidence, and suggests operational or strategic changes are needed to improve capital efficiency.

Cordlife Group Business Overview & Revenue Model

Company Description

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, gut microbiome banking, and lifestyle genetic screening services for adults. In addition, it offers Moms Up, a mobile application that offers parenting resources, as well as sprouts for health, wellness, and lifestyle needs. Further, the company provides medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.

How the Company Makes Money

Cordlife generates revenue primarily through its cord blood and cord tissue banking services, which involve one-time collection and processing fees followed by annual storage fees. The company charges parents for the initial collection and processing of the stem cells, and then continues to earn revenue through yearly storage fees for the samples. Additionally, Cordlife may also derive income from diagnostic services and healthcare products related to maternal and neonatal health. Strategic partnerships with hospitals and healthcare providers enhance its reach and customer base, contributing further to its earnings.

Cordlife Group Financial Statement Overview

Summary

Revenue is growing strongly (TTM +16.99%), but profitability is weak with deeply negative margins (net margin -29.53%, EBIT margin -38.58%). Balance sheet leverage is very low (debt-to-equity 0.0095), yet shareholder returns are negative (ROE -8.35%). Cash generation is pressured with negative operating cash flow and declining free cash flow growth (-18.82%).

Income Statement

Cordlife Group's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) data indicates a significant revenue growth rate of 16.99%, which is a positive sign. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -29.53% and a negative EBIT margin of -38.58%. The gross profit margin is relatively healthy at 56.00%, but the negative EBITDA margin of -28.15% highlights operational challenges. Overall, while revenue is growing, profitability remains a concern.

Balance Sheet

The balance sheet of Cordlife Group reflects a stable financial position with a low debt-to-equity ratio of 0.0095, indicating minimal leverage. However, the return on equity (ROE) is negative at -8.35%, suggesting inefficiencies in generating returns for shareholders. The equity ratio is strong, showing that a significant portion of the company's assets is financed by equity. Despite the low leverage, the negative ROE is a concern for potential investors.

Cash Flow

Cordlife Group's cash flow statement reveals challenges in cash generation. The TTM data shows a negative free cash flow growth rate of -18.82% and a negative operating cash flow. The free cash flow to net income ratio is positive at 1.61, indicating that the company is generating more free cash flow than net income, which is a positive aspect. However, the negative operating cash flow to net income ratio highlights ongoing cash flow issues. Overall, the cash flow situation is concerning, with significant room for improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.62M	27.84M	55.73M	55.16M	56.67M	44.66M
Gross Profit	16.03M	11.73M	37.30M	37.19M	39.48M	30.37M
EBITDA	-8.06M	-14.38M	8.56M	9.34M	10.78M	4.85M
Net Income	-8.45M	-18.69M	3.52M	4.89M	6.13M	4.96M
Balance Sheet
Total Assets	207.39M	217.14M	228.46M	228.00M	233.71M	176.58M
Cash, Cash Equivalents and Short-Term Investments	51.98M	60.58M	65.01M	65.17M	64.63M	71.96M
Total Debt	1.06M	2.42M	3.50M	2.22M	2.97M	5.79M
Total Liabilities	95.53M	98.68M	92.81M	93.67M	97.02M	75.71M
Stockholders Equity	111.61M	118.21M	135.33M	134.06M	136.43M	100.77M
Cash Flow
Free Cash Flow	-7.39M	-15.62M	6.96M	5.32M	7.93M	11.17M
Operating Cash Flow	-4.58M	-11.31M	9.80M	7.71M	9.50M	12.04M
Investing Cash Flow	-5.46M	-2.81M	-2.63M	4.43M	-23.91M	-1.01M
Financing Cash Flow	5.34M	7.17M	-1.86M	-13.45M	3.37M	-2.16M

Cordlife Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.13
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:P8A, the sentiment is Positive. The current price of 0.13 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.14, and below the 200-day MA of 0.20, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.11 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:P8A.

Cordlife Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1B1	67 Neutral	S$56.91M	6.29	47.36%	3.37%	1.58%	115.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
P8A	49 Neutral	S$38.30M	-3.51	-9.26%	―	2.83%	-0.71%